Vaccinex reports pepinemab significantly reduces GFAP biomarker in Huntington's disease; presented at CTAD.

VACCINEX, INC.

Pepinemab reduced plasma GFAP levels in HD patients vs placebo using highly sensitive S-PLEX immunoassay.
Data from podium presentation at CTAD Conference in Boston on October 26, 2023.
Prior phase 2 HD trial showed pepinemab prevented decline in glucose uptake and slowed cognitive decline (HD-CAB).
Ongoing SIGNAL-AD trial in Alzheimer's; last patient to complete 12-month treatment expected by June 2024.
Company sees pepinemab as potential alternative or complement to anti-Aβ antibodies for Alzheimer's.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.